本文已被：浏览 595次 下载 366次
Received:August 06, 2021 Published Online:February 20, 2022
Received:August 06, 2021 Published Online:February 20, 2022
中文摘要: 目的 探讨化痰逐瘀散结汤联合放化疗对Ⅲ期非小细胞肺癌患者免疫功能及生活质量的影响。方法 将2018年6月到2020年1月邯郸市第一医院收治的86例Ⅲ期非小细胞肺癌患者随机分配到研究组与对照组，各43例。研究组患者行化痰逐瘀散结汤联合放化疗治疗，对照组患者仅接受放化疗。所有患者于治疗完成后进行评价，比较两组患者机体免疫功能指标、生活质量评分和毒副反应情况。结果 治疗后，研究组KPS评分改善情况优于对照组（P＜0.01）。研究组骨髓抑制、消化道反应、放射性肺炎发生情况少于对照组，差异有统计学意义（P＜0.05，P＜0.01）。研究组CD3+细胞、CD4+细胞、CD4+/CD8+比值、IgG、IgM和IgA高于治疗前及对照组水平（P＜0.05）。结论 对Ⅲ期非小细胞肺癌患者，采用化痰逐瘀散结汤联合放化疗治疗可以提高患者机体免疫功能、改善生活质量及减轻毒副反应。
Abstract:Objective To investigate the effect of Huatan Zhuyu Sanjie Decoction(HZSD) combined with radiotherapy and chemotherapy on immune function and quality of life in patients with stage Ⅲ non-small cell lung cancer (NSCLC). Methods A total of 86 patients with stage Ⅲ NSCLC treated in Handan First Hospital from June 2018 to January 2020 were randomly assigned to the study group and the control group (n=43, each). HZSD combined with radiotherapy and chemotherapy was given in study group, while the radiotherapy and chemotherapy were conducted alone in control group. Immune function, quality of life score and toxic and side effects were compared after treatment between two groups. Results The improvement of Karnofsky performance scale (KPS) score in study group was significantly superior to that in control group (P＜0.01). The incidence of bone marrow suppression, gastrointestinal reaction and radiation pneumonia in study group was significantly lower than that in control group (P<0.05, P<0.01). The levels of CD3, CD4, CD4 /CD8 ratio as well as IgG, IgM and IgA in study group were significantly higher than those before treatment and those in control group (P<0.05). Conclusion Huatan Zhuyu Sanjie decoction combined with radiotherapy and chemotherapy can enhance the immune function, improve the quality of life, and reduce the side effects for the patients with stage Ⅲ NSCLC.
文章编号： 中图分类号：R273 文献标志码：B
基金项目:河北省中医药类科研计划课题（2019385）
引用文本：